LORBRENA vs RETEVMO

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated August 20, 2026·How we rate

Possible drug interaction. LORBRENA and RETEVMO are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	LORBRENA	RETEVMO
Rating	64/100	New
Pharmacy pays	—	—
Type	RX	RX
Active ingredient	LORLATINIB	SELPERCATINIB
Manufacturer	Pfizer	Eli Lilly and Co
Dosage forms	Tablet	Capsule, Tablet
Drug class	Kinase Inhibitor	Kinase Inhibitor
Boxed warning	None	None
Treats	—	Non-Small-Cell Lung Carcinoma, Thyroid Neoplasms

lorbrena retevmo

Rating

64/100

New

Pharmacy pays

—

Type

Active ingredient

LORLATINIB

SELPERCATINIB

Manufacturer

Pfizer

Eli Lilly and Co

Dosage forms

Tablet

Capsule, Tablet

Drug class

Kinase Inhibitor

Boxed warning

None

Treats

—

Non-Small-Cell Lung Carcinoma, Thyroid Neoplasms

Frequently asked questions

What is the difference between Lorbrena and Retevmo?

Lorbrena contains Lorlatinib, while Retevmo contains Selpercatinib — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.